Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583–1590. PMID: 24976103.
   PubMed Web of Science ®Google Scholar
• Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600–1611. PMID: 26474317.
   PubMed Web of Science ®Google Scholar
• Chen H, Ritz B. The search for environmental causes of parkinson’s disease: moving forward. J Parkinsons Dis. 2018;8(s1):S9–S17. PMID: 30584168; PMCID: PMC6311360.
   PubMedGoogle Scholar
• Liu R, Young MT, Chen JC, et al. Ambient air pollution exposures and risk of parkinson disease. Environ Health Perspect. 2016 Nov;124(11):1759–1765. PMID: 27285422; PMCID: PMC5089873.
   PubMed Web of Science ®Google Scholar
• Nishiwaki H, Ito M, Ishida T, et al. Meta-analysis of gut dysbiosis in parkinson’s disease. Mov Disord. 2020 Sep;35(9):1626–1635. PMID: 32557853.
   PubMed Web of Science ®Google Scholar
• Dickson DW. Neuropathology of parkinson disease. Parkinsonism Relat Disord. 2018;46 Suppl 1(Suppl 1):S30–S3.
   PubMedGoogle Scholar
• Fearnley JM, Lees AJ. Ageing and parkinson’s disease: substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5)):2283–2301. PMID: 1933245.
   PubMedGoogle Scholar
• Kasanuki K, Heckman MG, Diehl NN, et al. Regional analysis and genetic association of nigrostriatal degeneration in lewy body disease. Mov Disord. 2017 Nov;32(11):1584–1593. PMID: 28949048; PMCID: PMC5915345.
   PubMed Web of Science ®Google Scholar
• Chu HY. Synaptic and cellular plasticity in parkinson’s disease. Acta Pharmacol Sin. 2020 Apr;41(4):447–452. PMID: 32112041; PMCID: PMC7470833.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in parkinson’s disease. Brain. 2013 Aug;136(8):2419–2431. PMID: 23884810; PMCID: PMC3722357.
   PubMedGoogle Scholar
• Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic parkinson’s disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197–211. PMID: 12498954.
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the lewy body to the pathogenesis of idiopathic parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. PMID: 2841426; PMCID: PMC1033142.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591–1601. PMID: 26474316.
   PubMed Web of Science ®Google Scholar
• Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in alzheimer and parkinson diseases. Arch Neurol. 2003;60(3):337–341.
   PubMedGoogle Scholar
• Albin RL, Leventhal DK. The missing, the short, and the long: levodopa responses and dopamine actions. Ann Neurol. 2017 Jul;82(1):4–19. PMID: 28543679; PMCID: PMC5526730.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Blazquez C, Schrag A, Rizos A, et al. Prevalence of non-motor symptoms and non-motor fluctuations in parkinson’s disease using the MDS-NMS. Mov Disord Clin Pract. 2020 Dec 21;8(2):231–239. PMID: 33553493; PMCID: PMC7853195.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in parkinson’s disease. Mov Disord. 2009 Aug 15;24(11):1641–1649. PMID: 19514014.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, NMSS Validation Group, et al. The impact of non-motor symptoms on health-related quality of life of patients with parkinson’s disease. Mov Disord. 2011 Feb 15;26(3):399–406. PMID: 21264941.
   PubMed Web of Science ®Google Scholar
• Kurihara K, Nakagawa R, Ishido M, et al. Impact of motor and nonmotor symptoms in parkinson disease for the quality of life: the Japanese quality-of-life survey of parkinson disease (JAQPAD) study. J Neurol Sci. 2020 Dec 15;419:117172. PMID: 33065494.
   PubMed Web of Science ®Google Scholar
• Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of parkinson’s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229–238.
   PubMed Web of Science ®Google Scholar
• Bastide MF, Meer WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in parkinson’s disease. Prog Neurobiol. 2015 Sep;132:96–168. PMID: 26209473.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248–1266. Erratum in: Mov Disord. 2018 Dec;33(12):1992. PMID: 29570866.
   PubMed Web of Science ®Google Scholar
• Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000 Mar-Apr;23(2):82–85. PMID: 10803797.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of parkinson’s disease. Mov Disord. 2011 Oct;26 Suppl 3(03):S42–80. PMID: 22021174; PMCID: PMC4020145.
   PubMedGoogle Scholar
• Fariello RG, McArthur RA, Bonsignori A, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998 May;285(2):397–403.
   PubMed Web of Science ®Google Scholar
• Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem. 1998 Feb 12 41(4):579–590.
   PubMed Web of Science ®Google Scholar
• Benedetti MS, Tocchetti P, Rocchetti M, et al. Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Prog Brain Res. 1995;106:123–134.
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18–23.
   PubMed Web of Science ®Google Scholar
• Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999 Mar;288(3):1151–1159.
   PubMed Web of Science ®Google Scholar
• Morari M, Brugnoli A, Pisanò CA, et al. Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J Pharmacol Exp Ther. 2018 Feb;364(2):198–206.
   PubMed Web of Science ®Google Scholar
• Gardoni F, Morari M, Kulisevsky J, et al. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J Pharmacol Exp Ther. 2018 Dec;367(3):442–451.
   PubMed Web of Science ®Google Scholar
• Guerra A, Suppa A, D’Onofrio V, et al. Abnormal cortical facilitation and L-dopa-induced dyskinesia in parkinson’s disease. Brain Stimul. Nov-Dec 2019;12(6):1517–1525.
   PubMed Web of Science ®Google Scholar
• Marzo A, Bo L D, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004 Jul;50(1):77–85.
   PubMed Web of Science ®Google Scholar
• Seithel-Keuth A, Johne A, Freisleben A, et al. Absolute bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. Clin Pharmacol Drug Dev. 2013 Jan;2(1):79–89.
   PubMed Web of Science ®Google Scholar
• Müller T. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage parkinson’s disease. Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693–699.
   PubMed Web of Science ®Google Scholar
• Sadeghian M, Mullali G, Pocock JM, et al. Neuroprotection by safinamide in the 6-hydroxydopamine model of parkinson’s disease. Neuropathol Appl Neurobiol. 2016 Aug;42(5):423–435.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early parkinson disease by safinamide. Neurology. 2004 Aug 24;63(4):746–748. PMID: 15326260.
   PubMed Web of Science ®Google Scholar
• Chazot PL. Safinamide (newron pharmaceuticals). Curr Opin Invest Drugs. 2001 Jun;2(6):809–813. PMID: 11572661.
   PubMedGoogle Scholar
• Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early parkinson’s disease patients. Mov Disord. 2012 Jan;27(1):106–112. PMID: 21913224.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early parkinson’s disease. Eur J Neurol. 2013 Feb;20(2):271–280. PMID: 22967035.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in parkinson’s disease with motor fluctuations. Mov Disord. 2014 Feb;29(2):229–237. PMID: 24323641; PMCID: PMC4285943.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late parkinson’s disease. Mov Disord. 2014 Sep;29(10):1273–1280. PMID: 25044402.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017 Feb 1;74(2):216–224. PMID: 27942720.
   PubMed Web of Science ®Google Scholar
• Arevalo GG, Jorge R, Garcia S, et al. Clinical and pharmacological differences in early- versus late-onset parkinson’s disease. Mov Disord. 1997 May;12(3):277–284. PMID: 9159719.
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Moore CG, Leurgans SE, et al. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr;60(4):529–533. PMID: 12707066.
   PubMedGoogle Scholar
• Lenka A, Padmakumar C, Pal PK, et al. Treatment of older parkinson’s disease. Int Rev Neurobiol. 2017;132:381–405. PMID: 28554416.
   PubMed Web of Science ®Google Scholar
• Rinaldi D, Bianchini E, Sforza M, et al. The tolerability, safety and efficacy of safinamide in elderly parkinson’s disease patients: a retrospective study. Aging Clin Exp Res. 2021 Jul;33(6):1689–1692. PMID: 32681474.48.
   PubMed Web of Science ®Google Scholar
• Hattori N, Tsuboi Y, Yamamoto A, ME2125-3 Study Group, et al. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with parkinson’s disease: a randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat Disord. 2020 Jun;75:17–23. PMID: 32446176.
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Hattori N, Yamamoto A, ME2125-4 Study Group, et al. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with parkinson's disease with wearing-off: results of an open-label study. J Neurol Sci. 2020 Sep 15;416:117012. PMID: 32673884.
   PubMed Web of Science ®Google Scholar
• Grégoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013 May;19(5):508–514. PMID: 23402994.
   PubMed Web of Science ®Google Scholar
• Gardoni F, Morari M, Kulisevsky J, et al. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia. J Pharmacol Exp Ther. 2018 Dec;367(3):442–451. PMID: 30291173.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Ferla RL, Bonizzoni E, et al. Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475–481. PMID: 26406127; PMCID: PMC4923744.
   PubMedGoogle Scholar
• Ahmed MAA. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with parkinson’s disease. F1000Res. 2019 Dec 10;8:2078. PMID: 32431802; PMCID: PMC7205357.
   PubMedGoogle Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of parkinson’s disease on the quality of life. Mov Disord. 2005 Feb;20(2):224–230. PMID: 15384126.
   PubMed Web of Science ®Google Scholar
• Wasner G, Deuschl G. Pains in parkinson disease—many syndromes under one umbrella. Nat Rev Neurol. 2012 Apr 17;8(5):284–294. PMID: 22508236.
   PubMed Web of Science ®Google Scholar
• Broen MP, Braaksma MM, Patijn J, et al. Prevalence of pain in parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012 Apr;27(4):480–484. PMID: 22231908.
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in parkinson’s disease. Mov Disord. 2010;25(Suppl 1):S98–103. PMID: 20187254.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tinazzi M, Abbruzzese G, et al. Pain in parkinson’s disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917–e69. PMID: 29520899.
   PubMed Web of Science ®Google Scholar
• Choi SM, Kim BC, Jung HJ, et al. Impact of pain and pain subtypes on the quality of life of patients with parkinson’s disease. J Clin Neurosci. 2017 Nov;45:105–109. PMID: 28844618.
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in parkinson’s disease. Clin Neurosci. 1998;5(2):63–72. PMID: 10785830.
   Google Scholar
• Chaudhuri KR, Rizos A, Trenkwalder C, et al. King’s parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015 Oct;30(12):1623–1631. PMID: 26096067.
   PubMed Web of Science ®Google Scholar
• Rukavina K, Leta V, Sportelli C, et al. Pain in parkinson’s disease: new concepts in pathogenesis and treatment. Curr Opin Neurol. 2019 Aug;32(4):579–588. PMID: 31260418.
   PubMed Web of Science ®Google Scholar
• Beiske AG, Loge JH, Rønningen A, et al. Pain in parkinson’s disease: prevalence and characteristics. Pain. 2009 Jan;141(1–2):173–177. PMID: 19100686.
   PubMed Web of Science ®Google Scholar
• Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995 Jan;60(1):3–38. PMID: 7715939.
   PubMed Web of Science ®Google Scholar
• Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of parkinson disease: evidence from a case-control study. Arch Neurol. 2008 Sep;65(9):1191–1194. PMID: 18779422.
   PubMedGoogle Scholar
• Schapira A, Fox S, Hauser R, et al. SETTLE study design: a 24-week, double blind, placebocontrolled study of the efficacy and safety of safinamide as add on therapy to levodopa in patients with parkinson’s disease. Movement Disorders Society 14th International Congress (Poster); 2010; 25, (Suppl 2), S308. Buenos Aires.
   Google Scholar
• Cattaneo C, Barone P, Bonizzoni E, et al.Effects of safinamide on pain in fluctuating parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95–101. PMID: 27802242; PMCID: PMC5302028.
   PubMedGoogle Scholar
• Cattaneo C, Kulisevsky J, Tubazio V, et al. Long-term efficacy of safinamide on parkinson’s disease chronic pain. Adv Ther. 2018 Apr;35(4):515–522. PMID: 29542008; PMCID: PMC5910467.
   PubMed Web of Science ®Google Scholar
• Geroin C, Di Vico IA, Squintani G, et al. Effects of safinamide on pain in parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm (Vienna). 2020 Aug;127(8):1143–1152. PMID: 32572581.
   PubMed Web of Science ®Google Scholar
• Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999 Mar;288(3):1151–1159. PMID: 10027853.
   PubMed Web of Science ®Google Scholar
• Miladinovic T, Nashed MG, Singh G, et al. Overview of glutamatergic dysregulation in central pathologies. Biomolecules. 2015 Nov 11;5(4):3112–3141. PMID: 26569330; PMCID: PMC4693272.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Müller T, Bonizzoni E, et al. Long-term effects of safinamide on mood fluctuations in parkinson’s disease. J Parkinsons Dis. 2017;7(4):629–634. PMID: 28777756; PMCID: PMC5676861.
   PubMedGoogle Scholar
• Peña E, Borrué C, Mata M, et al. Impact of safinamide on depressive symptoms in parkinson’s disease patients (SADness-PD study): a multicenter retrospective study. Brain Sci. 2021 Feb 13;11(2):232. PMID: 33668408; PMCID: PMC7918129.
   PubMed Web of Science ®Google Scholar
• Rinaldi D, Sforza M, Assogna F, et al. Safinamide improves executive functions in fluctuating parkinson’s disease patients: an exploratory study. J Neural Transm (Vienna). 2021 Feb;128(2):273–277. PMID: 33068177.
   PubMed Web of Science ®Google Scholar
• Liguori C, Stefani A, Ruffini R, et al. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating parkinson's disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord. 2018 Dec;57:80–81. PMID: 30006034.
   PubMed Web of Science ®Google Scholar
• Gómez-López A, Sánchez-Sánchez A, Natera-Villalba E, et al. SURINPARK: safinamide for urinary symptoms in parkinson’s disease. Brain Sci. 2021 Jan 6;11(1):57. PMID: 33418858; PMCID: PMC7825064.
   PubMed Web of Science ®Google Scholar
• Liguori C, Mercuri NB, Stefani A, et al. Effective treatment of restless legs syndrome by safinamide in parkinson’s disease patients. Sleep Med. 2018 Jan;41:113–114. PMID: 29268951.
   PubMed Web of Science ®Google Scholar
• Santos García D, Labandeira Guerra C, Yáñez Baña R, et al. Safinamide improves non-motor symptoms burden in parkinson’s disease: an open-label prospective study. Brain Sci. 2021 Mar 2;11(3):316. PMID: 33801565; PMCID: PMC7999475.
   PubMed Web of Science ®Google Scholar
• Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016 Oct 18;7:340. PMID: 27803666; PMCID: PMC5067815.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Ionescu DF, Richards EM, et al. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014 Aug;121(8):907–924. PMID: 24318540; PMCID: PMC4048804.
   PubMed Web of Science ®Google Scholar
• Yu X, Li W, Ma Y, et al. GABA and glutamate neurons in the VTA regulate sleep and wakefulness. Nat Neurosci. 2019 Jan;22(1):106–119. PMID: 30559475; PMCID: PMC6390936.
   PubMed Web of Science ®Google Scholar
• Morari M, Brugnoli A, Pisanò CA, et al. Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J Pharmacol Exp Ther. 2018 Feb;364(2):198–206. PMID: 29167350.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Gross A, Finberg JP, et al. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132(2):500–506. PMID: 11159700; PMCID: PMC1572573.
   PubMed Web of Science ®Google Scholar
• Gerlach M, Youdim MB, Riederer P, et al. Pharmacology of selegiline. Neurology. 1996;47(6 Suppl 3):S137–45. PMID: 8959982.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978;6(6):542–544. PMID: 728327; PMCID: PMC1429688.
   PubMed Web of Science ®Google Scholar
• Leegwater-Kim J, Bortan E. The role of rasagiline in the treatment of parkinson’s disease. Clin Interv Aging. 2010;5:149–156. PMID: 20517484; PMCID: PMC2877525.
   PubMed Web of Science ®Google Scholar
• Avila A, Caballol N, Martín-Baranera M, et al. Rasagiline and safinamide as a dopamine-sparing therapy for parkinson’s disease. Acta Neurol Scand. 2019;140(1):23–31. Epub 2019 Apr 22. PMID: 30963543.
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Kulisevsky J, Bergmans B, et al. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial. J Parkinsons Dis. 2021;11(1):187–198. PMID: 33104040; PMCID: PMC7990425.
   PubMedGoogle Scholar
• Macleod AD, Counsell CE, Ives N, et al. Monoamine oxidase B inhibitors for early parkinson’s disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. PMID: 16034956. DOI:10.1002/14651858.CD004898.pub2
   PubMed Web of Science ®Google Scholar
• Binde CD, Tvete IF, Gåsemyr J, et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for parkinson’s disease. Br J Clin Pharmacol. 2018 Sep;84(9):1917–1927. Epub 2018 Jun 25. PMID: 29847694; PMCID: PMC6089809.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Safinamide. 2019 Apr 8. PMID: 31644126.
   Google Scholar